POSTER: AML-412 Bleximenib Dose Optimization and Determination of the Recommended Phase 2 Dose (RP2D) From a Phase 1 Study in Patients With Relapsed/Refractory Acute Leukemia (AL) With KMT2A and NPM1 Alterations
Year: 2025
Type: article
Authors: Hagop M. Kantarjian, Emma Searle, Christian Recher, Maher Abdul-Hay, Sameem Abedin, Ibrahim Aldoss, Ana Alfonso Pierola, Juan M. Alonso-Dominguez, Patrice Chevallier, Carrye Cost, Nikki Daskalakis, Richard Dillon, Neil Dunavin, Jordi Esteve, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Min Chul Kwon, Anita J. Kumar, Teng Fong Ng, Kathryn Packman, Ulrike Philippar, Arnaud Pigneux, Olga Salamero, Madhu Sanga, Prathap Nagaraja Shastri, Richard M. Stone, Peter Tan, Trevor Tucker, Paresh Vyas, Sylvain Garciaz
Institutions: The University of Texas MD Anderson Cancer Center, University of Manchester, The Christie NHS Foundation Trust, Institut universitaire du cancer de Toulouse Oncopole, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Medical College of Wisconsin, City Of Hope National Medical Center, Clinica Universidad de Navarra, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Centre Hospitalier Universitaire de Nantes, Janssen Research & Development (United States), King's College London, Guy's and St Thomas' NHS Foundation Trust, University of California, San Francisco, Hospital Clínic de Barcelona, Harvard University, Massachusetts General Hospital, Monash Health, Monash University, Janssen (Belgium), Centre Hospitalier Universitaire de Tours, Gold Coast Hospital, Hôpital Cardiologique du Haut-Lévêque, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Dana-Farber Cancer Institute, Royal Perth Hospital, University of Oxford, MRC Weatherall Institute of Molecular Medicine, Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4413788814